Insulet (PODD) Stock
Tubeless insulin pump maker with recurring consumables revenue. Here's the price, business snapshot, and what's worth knowing about Insulet in October 2026.
Insulet Corporation (PODD) is a medical‑device company best known for its Omnipod tubeless insulin pump system, aimed at people with type 1 and insulin‑dependent type 2 diabetes. The business model centres on device sales and recurring pod consumables, with supplementary software and services that support automated insulin delivery. With a market capitalisation of roughly $23.2 billion, growth prospects hinge on rising adoption of insulin‑delivery technology, tighter integration with continuous glucose monitoring and expansion into international markets. Key investor considerations include manufacturing scale‑up, reimbursement and regulatory pathways, competition from established pump makers and integrated diabetes platforms, and execution risk around new product roll‑outs. Financial performance can be variable and past performance is not a guarantee of future returns. This is general educational information only and not personal advice; investors should assess suitability for their own circumstances and may wish to consult a regulated financial adviser.
Why It’s Moving
Insulet Sets Date for Q3 Earnings Release, Keeping Investors on Watch
- The company will release Q3 2026 financial results before the opening of the financial markets on November 4, 2026.
- Management plans to host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the findings.
- As the global leader in tubeless insulin pump technology, Insulet's upcoming data will be closely scrutinized for signs of continued growth in the diabetes care sector.
Insulet Sets Date for Q3 Earnings Release, Keeping Investors on Watch
- The company will release Q3 2026 financial results before the opening of the financial markets on November 4, 2026.
- Management plans to host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the findings.
- As the global leader in tubeless insulin pump technology, Insulet's upcoming data will be closely scrutinized for signs of continued growth in the diabetes care sector.
Sixth Month Growth Performance
When is the next earnings date for INSULET CORPORATION (PODD)?
No confirmed upcoming earnings date has been announced for PODD as of the current reporting cycle. Based on the historical pattern where reports typically occur approximately three months after the previous quarter's close, the next release is expected in November 2026. This upcoming report will cover the company's third-quarter fiscal results for 2026. Investors should monitor official channels for the precise scheduling of this anticipated announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Insulet's stock with a target price of $231.36, indicating strong growth potential.
Financial Health
Insulet Corporation shows strong revenue, profits, and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Growth from Adoption
Increasing uptake of insulin‑delivery technology could drive revenue through devices and recurring pods, though adoption rates and reimbursement vary by market.
International Expansion
Rolling out into new regions offers scale potential, balanced against regulatory approvals, local reimbursement and distribution challenges.
Innovation & Partnerships
Integration with continuous glucose monitors and progress toward automated insulin delivery can be strategic catalysts, yet execution and competition are material risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
